文献速递银屑病与炎症性皮肤病

银屑病生物制剂免疫原性:误区、事实与管理建议

Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-01-01

本文综述银屑病生物制剂的抗药抗体(ADA)免疫原性,指出不同药物ADA报告率因检测方法、试验设计和患者人群等因素难以直接比较,并基于III期数据提出将生物制剂按临床相关ADA风险分为三组的工作分类及管理思路。

要点

  • ADA检测方法、试验设计及患者人群差异使跨药免疫原性比较不可靠。
  • 基于III期数据提出按临床相关ADA风险将生物制剂分为三组。
  • 该分组为工作概念,需采用可比ADA检测和一致结局报告进一步研究。

核心结论

  • 不同生物制剂ADA报告率存在差异,但无公认的皮肤科指南或风险分组。
  • 基于III期免疫原性数据提出按临床相关ADA风险分三组的工作分类。
  • 需更多采用可比ADA检测和一致结局报告的研究验证分组。

研究设计与样本

  • 综述类文章,概述ADA概念并汇总银屑病常用生物制剂的III期免疫原性数据。

主要发现

  • ADA检测方法、试验设计、纳入患者人群及生物制剂分子结构均影响ADA报告率和临床反应。
  • 不同生物制剂ADA报告率存在明显差异。

关键数值与推荐

  • 提出工作分类:第1组为临床相关ADA风险较高;第2组为风险较低;第3组为无确立风险。

临床怎么用

  • 临床医生应熟悉ADA概念,并参考工作分类管理银屑病生物制剂免疫原性。
  • 因证据局限,分组仅作工作概念,需结合更多研究指导临床决策。

局限性

  • 跨药免疫原性比较因ADA检测方法、试验设计和患者人群差异而存在根本缺陷。
  • 分组为工作概念,需更多采用可比ADA检测和一致结局报告的研究。
  • 需更好识别ADA高风险个体以指导临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With biologic drugs dominating the therapeutic space for severe immune-mediated inflammatory disease, it is critical for clinicians to be familiar with the concept of drug immunogenicity, with the potential for our patients to develop antidrug antibodies (ADA) of clinical relevance. Whilst there are clear differences between different therapeutic biologics in terms of reported ADA rates, there is no accepted dermatology guideline or grouping of drugs by risk of clinically relevant ADA, nor a consensus on approach to ADA management. This is partly because making valid comparisons of immunogenicity across drugs is fundamentally flawed: the differing types of ADA assay, trial design and included patient population - as well as the molecular structure of the biologic molecules themselves - are all highly influential on reported ADA prevalence and impact on clinical response. Therefore, the first part of this article aims to give an overview of ADA that also clarifies common misconceptions on the subject, whilst the second part of this article outlines Phase III immunogenicity data on commonly used biologics for psoriasis, the most common dermatological indication. Based on this, and acknowledging current limitations in available evidence, we propose a working categorization of biologics together with a broad approach to management: Group 1 - biologics with higher risk of clinically relevant ADA; Group 2 - biologics with lower risk of clinically relevant ADA; and Group 3 - biologics with no established risk of clinically relevant ADA. However, these groupings represent a working concept only; more research is required, using comparable ADA assays and consistent reporting of related outcomes. Finally, there is an urgent need for better characterization of individuals at particular risk of developing ADA to inform future clinical decision-making.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Tsakok T, Rispens T, Spuls P, et al. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. J Eur Acad Dermatol Venereol. 2021. PMID: 33030275. doi:10.1111/jdv.16980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。